December 28, 2016Hepatology ResearchOpen Access

Combined treatment with dipeptidyl peptidase‐4 inhibitor (sitagliptin) and angiotensin‐II type 1 receptor blocker (losartan) suppresses progression in a non‐diabetic rat model of steatohepatitis

Q: What is the clinical evidence from this study?

Population: Nonalcoholic steatohepatitis (NASH) (n=50). Intervention: Sitagliptin and losartan combination vs. Vehicle (PBS), sitagliptin monotherapy, or losartan monotherapy. Primary outcome: Hepatic fibrogenesis and carcinogenesis.

View Full Paper

Ask AI

Bookmark

Key result

Combination treatment with sitagliptin and losartan significantly suppressed hepatic fibrogenesis and carcinogenesis in a rat model of NASH, exerting a greater inhibitory effect than monotherapy.

Why the study?

Does the combination of sitagliptin and losartan suppress hepatic fibrogenesis and carcinogenesis in a non-diabetic rat model of NASH?

Structured PICO

Does the combination of sitagliptin and losartan suppress hepatic fibrogenesis and carcinogenesis in a non-diabetic rat model of NASH?

Population

50 6-week-old male Fischer 344 rats with CDAA diet-induced NASH, treated for 12 weeks.

Intervention

Sitagliptin (150 mg/kg/day) and losartan (30 mg/kg/day) via daily oral gavage for 12 weeks

Comparator

CDAA diet + phosphate-buffered saline (vehicle), CDAA diet + sitagliptin monotherapy, CDAA diet + losartan monotherapy, and choline-sufficient L-amino acid-defined (CSAA) diet + distilled water (negative control)

Outcome

Hepatic fibrogenesis and carcinogenesissurrogate

Limitations

Animal model may not fully replicate human NASH
Discrepancy in DPP4 activity among different organs and tissues
The exact mechanism underlying the enhancement of the anticarcinogenic properties of sitagliptin in NASH progression remains unclear

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Combined DPP4-I/ARB therapy merits human trials for fibrosis; animal data leave efficacy and safety open.

Cite This Study

Okura et al. (2016) studied Nonalcoholic steatohepatitis (NASH) (n=50). Sitagliptin and losartan combination vs. Vehicle (PBS), sitagliptin monotherapy, or losartan monotherapy was evaluated on Hepatic fibrogenesis and carcinogenesis. Combination treatment with sitagliptin and losartan significantly suppressed hepatic fibrogenesis and carcinogenesis in a rat model of NASH, exerting a greater inhibitory effect than monotherapy.

synapsesocial.com/papers/6a63d62c1d33332decb366bf https://doi.org/10.1111/hepr.12860

View Full Paper

Ask AI

Bookmark

Combined treatment with dipeptidyl peptidase‐4 inhibitor (sitagliptin) and angiotensin‐II type 1 receptor blocker (losartan) suppresses progression in a non‐diabetic rat model of steatohepatitis

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Combined treatment with dipeptidyl peptidase‐4 inhibitor (sitagliptin) and angiotensin‐II type 1 receptor blocker (losartan) suppresses progression in a non‐diabetic rat model of steatohepatitis

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider